[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Mioulet D, Braem L, Heno P, Paule P, Peloni JM, Bonnet D, Fourcade L: [Cardiac extension of a non-Hodgkin lymphoma revealed by an atrial flutter]. Ann Cardiol Angeiol (Paris); 2009 Apr;58(2):117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac extension of a non-Hodgkin lymphoma revealed by an atrial flutter].
  • Primary or secondary cardiac lymphomas are not frequent.
  • Our case report, which is a slow atrial flutter with a pericardial effusion, is an uncommon discovery mode for a malignant lymphoma.
  • Their diagnosis and the mechanism of the arythmia were allowed by non-invasive cardiac imagery (transesophageal echography and magnetic resonance imaging), which showed a tumour-like infiltration of the right atrium, of the right ventricle posterior wall, and of the atrioventricular junction.
  • The diagnosis of a high grade B cell malignant non-hodgkin lymphoma, involving the bone marrow, the liver and the kidneys was made by biopsies of lymph nodes, histological analysis of the bone marrow, and a body CT scan.
  • Throughout the first chemotherapy sequence, we observed a spontaneous return to a sinusal rhythm, and the cardiac MRI showed a regression of the myocardial infiltration and of the pericardial effusion; moreover, the patient's state improved and the peripheral lymph nodes shrank back to a normal size.
  • However, the patient passed away, due to neurological complications 13 months after the diagnosis of lymphoma, without recurrence of cardiac involvement.
  • [MeSH-major] Atrial Flutter / etiology. Heart Neoplasms / complications. Lymphoma, B-Cell / complications

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657797.001).
  • [ISSN] 1768-3181
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Avilés A, Neri N, Nambo JM, Huerta-Guzman J, Talavera A, Cleto S: Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma; 2005 Jul;46(7):1023-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
  • Anthracyclines are a group of drugs that are useful in the treatment of Hodgkin's disease, but have been associated with severe, and in some cases lethal, cardiac toxicity.
  • Apparently, cardiac toxicity is more frequent after 10 years of anthracycline therapy, but no longer studies of cardiac toxicity have been reported.
  • The endpoint was the presence of a clinical cardiac event (CCE) or abnormalities in equilibrium radionuclide angiocardiography (ERNA) and echocardiogram.
  • The patients did not receive radiation therapy and when relapsed they were censored from cardiac toxicity.
  • Overall survival was better in patients treated with EBVD because less cardiac events were observed.
  • The use of mitoxantrone was associated with a high rate of relapse and cardiac events.
  • Thus, we would not recommend use of the drug in Hodgkin's disease.
  • ERNA and echocardiogram are early detection tests for cardiac toxicity and can be employed in surveillance studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Heart / drug effects. Heart Diseases / chemically induced. Hodgkin Disease / drug therapy. Mitoxantrone / adverse effects
  • [MeSH-minor] Adolescent. Adult. Bleomycin / adverse effects. Dacarbazine / adverse effects. Disease-Free Survival. Doxorubicin / adverse effects. Echocardiography. Epirubicin / adverse effects. Female. Gated Blood-Pool Imaging. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Survival Rate. Treatment Outcome. Vinblastine / adverse effects

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019553.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; ABVD protocol; EBVD protocol
  •  go-up   go-down


3. Avilés A, Nambo MJ, Neri N, Talavera A, Castañeda C, Murillo E, Cleto S, Huerta-Guzmán J: Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma. Med Oncol; 2004;21(3):269-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma.
  • The aim of the present study was to evaluate an intensive chemotherapy regimen in patients with diffuse large B-cell lymphoma and poor prognosis, as presence of high- or high-intermediate clinical risk, bulky disease, high levels of beta 2 microgloblin, and more than two extranodal sites of involvement at diagnosis.
  • Five died secondary to tumor progression, actuarial curves at 3-yr for overall survival were 75%.
  • Toxicity was mild, granulocytopenia grade III or IV were observed in the 46% of the cycles; infection-related granulocytopenia was observed in 17%, but no fatality due to therapy was observed.
  • Cardiac toxicity was mild, only seven patients showed a drop in left ejection ventricular function, but no symptomatic heart failure has been observed.
  • The intensive CEOP-Bleo regimen with increasing doses of cyclophosphamide and epirubicin is a useful and well-tolerated regimen in the treatment of poor prognosis diffuse large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Epirubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Prognosis. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Ann Intern Med. 1985 May;102(5):596-602 [2580468.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):651-6 [7694634.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2282-8 [9610711.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1018-26 [2474057.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):25-38 [1702144.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):757-65 [2422995.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3564-73 [8260695.001]
  • [Cites] Hematol J. 2001;2(4):279-85 [11920261.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):339-47 [1824863.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1275-81 [8648384.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2916-23 [8523055.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1309-15 [10715302.001]
  • (PMID = 15456955.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


Advertisement
4. Porea TJ, Dreyer ZE, Bricker JT, Mahoney DH Jr: Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study. J Pediatr Hematol Oncol; 2001 Oct;23(7):420-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study.
  • BACKGROUND: Cardiac toxicity is a well-recognized potential complication of anthracycline use.
  • Children treated with anthracyclines undergo several cardiac screening procedures before therapy, but the usefulness of these pretherapy cardiac studies has never been evaluated.
  • The authors examined whether induction chemotherapy in patients with high-risk acute lymphoblastic leukemia (ALL) was altered based on a pretherapy left ventricular shortening fraction (SF).
  • PATIENTS AND METHODS: Medical records of 134 children registered on treatment protocols of the Pediatric Oncology Group for high-risk B-precursor and T-cell ALL between 1987 and 1998 were reviewed.
  • Demographic information consisting of age at diagnosis, sex, and past cardiac history was collected, as were the results of all echocardiographic evaluations for SF and actions taken based on these evaluations.
  • The outcome measured was whether any changes were made in induction therapy based on initial SF.
  • In addition, secondary SF results obtained at the cumulative anthracycline dose range of 90 to 150 mg/m2 were studied to determine whether modifications of future chemotherapy were made after this limited exposure.
  • RESULTS: Three of 128 children (2.3%) without a previous cardiac history had an initial SF on their pretherapy echocardiogram that prompted additional evaluation but no change in therapy.
  • A secondary analysis of SF in 85 children who completed anthracycline doses of 90 to 150 mg/m2 was performed.
  • No cardiac dysfunction occurred among these six patients during later follow-up.
  • CONCLUSIONS: In the absence of a previous cardiac history or signs and symptoms or cardiac disease, pretherapy evaluation of left ventricular function may not be indicated in children about to undergo anthracycline-based treatment of acute leukemia.
  • The timing of initiation of cardiac evaluation remains unclear, but these results suggest that even at a cumulative dose of 90 to 150 mg/m2, studies to determine left ventricular function do not yield data sufficient to warrant a change in the clinical management of these patients.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Heart / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Ventricular Function, Left / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11878575.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


5. Durrleman N, El Hamamsy I, Demaria R, Carrier M, Perrault LP, Albat B: [Is Dacron carcinogenic? Apropos of a case and review of the literature]. Arch Mal Coeur Vaiss; 2004 Mar;97(3):267-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary malignant cardiac tumours are extremely rare.
  • The authors report a case of primary cardiac lymphoma nine years after implantation of a double leaflet mitral valve prosthesis.
  • Malignant lymphoma is a haematological form of sarcoma.
  • It typically presents as a nodular or diffuse myocardial infiltrate explaining its clinical expression as cardiac failure and atrioventricular block.
  • Survival after "pure" medical therapy (chemotherapy alone or associated with radiotherapy) is 6 to 8 months after diagnosis.
  • Dacron has been implicated in the pathogenesis of primary cardiac sarcoma.
  • In conclusion, although primary cardiac lymphoma is a rare condition, it should be considered, as with thrombosis, a possible differential diagnosis of acute dysfunction of cardiac valvular prostheses.
  • [MeSH-major] Heart Neoplasms / etiology. Heart Valve Prosthesis / adverse effects. Lymphoma, Large-Cell, Immunoblastic / etiology. Polyethylene Terephthalates / adverse effects
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / secondary. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asthenia / etiology. Diagnostic Errors. Fatal Outcome. Female. Humans. Mitral Valve / surgery. Multiple Organ Failure / etiology. Myxoma / diagnosis. Sarcoma / chemically induced. Thrombosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15106752.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Polyethylene Terephthalates
  • [Number-of-references] 10
  •  go-up   go-down


6. Lather N, Islam M, Fergus IV: Symptomatic metastatic right atrial lymphoma in a patient with AIDS presenting with pulmonary embolization. Rev Cardiovasc Med; 2008;9(4):275-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic metastatic right atrial lymphoma in a patient with AIDS presenting with pulmonary embolization.
  • Tumors involving the heart are rare, and the majority of them are benign.
  • Secondary lymphoma with localization to the heart is the third most common malignant heart tumor and is more common, by far, than primary cardiac lymphomas.
  • In patients with human immunodeficiency virus, the risk of development of systemic lymphoma is 60 to 200 times higher than in the general population.
  • Transthoracic echocardiography is the initial modality of choice for diagnosis of cardiac lymphomas because it is readily available and helps localize the tumor, but transesophageal echocardiography and magnetic resonance imaging remain the best tests for evaluation.
  • Treatment consists primarily of chemotherapy, and anticoagulation can be used in certain cases where embolization of the tumor is likely.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Heart Atria / pathology. Heart Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Embolism / virology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Echocardiography. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed


7. Kholová I, Kautzner J: Current treatment in cardiac amyloidosis. Curr Treat Options Cardiovasc Med; 2006 Dec;8(6):468-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment in cardiac amyloidosis.
  • Involvement of the heart is a common finding in amyloidosis.
  • The heart is usually infiltrated by amyloid fibrils in primary amyloidosis and age-related forms of amyloidosis, less commonly in transthyretin familial amyloidosis, and rarely in secondary amyloidosis.
  • The most common clinical presentation is restrictive cardiomyopathy with right-sided heart failure.
  • The second most frequent presentation is congestive heart failure due to systolic dysfunction, followed by arrhythmias and orthostatic hypotension.
  • The diagnosis of amyloidosis requires tissue sample confirmation; at present, Congo red staining in polarized light is the diagnostic method of choice.
  • The characterization of protein fibril type by immunohistochemistry or biochemistry is essential for patient prognosis and treatment.
  • The therapeutic approach consists of specific treatment of amyloidosis and supportive treatment for cardiac-related symptoms.
  • The treatment depends on the type of amyloidosis and the stage of disease.
  • The mainstay of supportive treatment of cardiac failure is diuretic therapy.
  • Primary amyloidosis treatment protocol includes melphalan and prednisone chemotherapy.
  • Heart transplantation is only a palliative treatment.
  • Stem cell transplantation is an emerging treatment alternative.
  • Combination therapy of melphalan and stem cell transplantation has been shown to be a promising treatment strategy.
  • Secondary amyloidosis requires aggressive treatment of the associated inflammatory and neoplastic process.
  • Age-related (senile) amyloidosis benefits from supportive cardiac treatment when applicable.
  • Transthyretin amyloidosis, the most common cardiac hereditary amyloidosis, is treated by liver or combined liver-heart transplantation.
  • New therapies based on chemical and immunologic reaction with amyloid or its precursor are under intensive development.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2003 Jul;443(1):3-16 [12802585.001]
  • [Cites] Am J Clin Pathol. 2001 Jul;116(1):135-42 [11447744.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):31466-73 [12070143.001]
  • [Cites] Mayo Clin Proc. 2002 Dec;77(12):1278-9 [12479511.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(7):591-6 [16062177.001]
  • [Cites] Nature. 2002 May 16;417(6886):254-9 [12015594.001]
  • [Cites] Tex Heart Inst J. 2005;32(2):178-84 [16107109.001]
  • [Cites] N Engl J Med. 1997 Apr 24;336(17):1202-7 [9110907.001]
  • [Cites] Clin Lymphoma. 2003 Mar;3(4):241-6 [12672274.001]
  • [Cites] N Engl J Med. 1997 Jan 23;336(4):267-76 [8995091.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2936-8 [15070667.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S160-3 [16286897.001]
  • [Cites] Kardiol Pol. 2005 Jul;63(7):20-35 [16136426.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):125-33 [15677530.001]
  • [Cites] Amyloid. 2002 Sep;9(3):197-200 [12408684.001]
  • [Cites] Lab Invest. 2004 May;84(5):545-52 [14968122.001]
  • [Cites] Curr Treat Options Cardiovasc Med. 2005 Dec;7(6):443-8 [16283971.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4276-82 [12036853.001]
  • [Cites] J Heart Lung Transplant. 2004 Oct;23 (10 ):1142-53 [15477107.001]
  • [Cites] J Med Chem. 2002 Jan 17;45(2):321-32 [11784137.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 May;125(5):1165-6 [12771895.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):886-9 [12060126.001]
  • [Cites] Circulation. 2005 Sep 27;112(13):2047-60 [16186440.001]
  • [Cites] Chest. 2001 Nov;120(5):1735-8 [11713162.001]
  • [Cites] Transplantation. 2003 Feb 27;75(4):560-1 [12605128.001]
  • [Cites] Heart. 2001 Feb;85(2):202-7 [11156673.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):131-5 [14508801.001]
  • [Cites] Circulation. 2002 Oct 15;106(16):2091-7 [12379579.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):4039-45 [12244207.001]
  • [Cites] Amyloid. 2001 Mar;8(1):52-7 [11293825.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1227-9 [16210334.001]
  • [Cites] J Intern Med. 2003 Sep;254(3):225-35 [12930231.001]
  • [Cites] Liver Transpl. 2003 Sep;9(9):986-92 [12942463.001]
  • [Cites] Amyloid. 2003 Jun;10(2):127-9 [12964421.001]
  • [Cites] Blood Rev. 2004 Mar;18(1):17-37 [14684147.001]
  • [Cites] Transplantation. 2001 Apr 15;71(7):986-92 [11349736.001]
  • [Cites] Curr Drug Targets. 2004 Feb;5(2):151-8 [15011948.001]
  • [Cites] Curr Opin Rheumatol. 2004 Jan;16(1):67-75 [14673392.001]
  • [Cites] Circulation. 2001 Dec 11;104(24):2996-3007 [11739319.001]
  • [Cites] Am J Med. 2002 Nov;113(7):549-55 [12459400.001]
  • [Cites] Kidney Int. 2002 Jan;61(1):1-9 [11786079.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:257-82 [15561687.001]
  • [Cites] Ann Intern Med. 2004 Jan 20;140(2):85-93 [14734330.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):88-95 [16612621.001]
  • [Cites] Bone Marrow Transplant. 2001 Aug;28(4):381-5 [11571511.001]
  • [Cites] N Engl J Med. 2005 Feb 17;352(7):722-3 [15716569.001]
  • [Cites] J Clin Pathol. 2003 Feb;56(2):86-90 [12560384.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):583-96 [12904524.001]
  • (PMID = 17078911.001).
  • [ISSN] 1092-8464
  • [Journal-full-title] Current treatment options in cardiovascular medicine
  • [ISO-abbreviation] Curr Treat Options Cardiovasc Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Gustavsson A, Osterman B, Cavallin-Ståhl E: A systematic overview of radiation therapy effects in Hodgkin's lymphoma. Acta Oncol; 2003;42(5-6):589-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic overview of radiation therapy effects in Hodgkin's lymphoma.
  • A systematic review of radiation therapy trials in several tumour types was carried out by The Swedish Council of Technology Assessment in Health Care (SBU).
  • This synthesis of the literature on radiation therapy for Hodgkin's lymphoma (HL) is based on data from 12 randomized trials and 2 meta-analyses.
  • The conclusions reached can be summarized thus: Solid scientific documentation shows that in patients with HL more than 80% in the early stages and 60-70% of younger patients in advanced stages of disease are now cured by the development of radiotherapy and combination chemotherapy.
  • Long-term follow-up shows that after 15 to 20 years the mortality from HL in early and intermediate stages is exceeded by other causes of death, mostly secondary malignancies and cardiac deaths, especially myocardial infarction.
  • During the past decade increasing awareness of fatal long-term sequelae has fundamentally changed treatment strategies in early and intermediate stages.
  • A thorough long-term follow-up is essential to evaluate the effects of the modifications of the therapy.
  • In early stages of disease extended field irradiation is now replaced by short periods of chemotherapy followed by limited radiotherapy to decrease late sequelae.
  • The optimal radiation dose and volume after chemotherapy are not defined or if irradiation is needed at all.
  • In intermediate stages two recently reported randomized trials indicate that combined modality therapy is preferable and that involved field could replace extended field irradiation.
  • There is no scientific support for improved survival with radiotherapy in conjunction with high-dose chemotherapy with stem-cell support.
  • Radiotherapy as salvage treatment might be an alternative in late limited nodal recurrence after initial chemotherapy.
  • The role of radiotherapy in the treatment of HL is decreasing.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Sweden. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14596517.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 72
  •  go-up   go-down


9. von der Weid NX: Adult life after surviving lymphoma in childhood. Support Care Cancer; 2008 Apr;16(4):339-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult life after surviving lymphoma in childhood.
  • The combined incidence of Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) reaches 10 to 12 new cases a year per million children under the age of 16 years, representing about 10% of all pediatric cancers.
  • Intrathecal or high-dose intravenous chemotherapy with methotrexate may induce the same problems, although in a lesser extent and severity.
  • Cardiac function must be serially evaluated over the long to very long-term because of potential cardiomyopathy after high anthracycline doses and/or mediastinal irradiation.
  • Radiation therapy to the neck and mediastinum (mantle field) induces a 50% risk of developing hypothyroidism and a 20% risk of developing thyroid nodules at 20 years.
  • The risk of thyroid cancer is 18 times higher the expected rate for the general population.
  • Secondary aggressive breast cancer shows a cumulative risk of 30% at 30 years after radiotherapy.
  • Other structures affected by mediastinal irradiation are the heart (pericardial, myocardial and endocardial structures), the great arteries (fibrosis, stenosis, aneurysms) and the central portion of the lungs (diffusion troubles, restrictive pneumopathy).
  • Cardiac toxicity can be enhanced by the concomitant therapy with adriamycin and lung toxicity by bleomycin.
  • Radiotherapy to the paraaortic and iliacal lymph nodes can affect gonadal function both in males and females; concomitant chemotherapy with alkylating agents like cyclophosphamide and especially procarbazine have a synergistic action and can lead to premature menopause as well as infertility.
  • Although the vast majority of survivors from pediatric lymphomas fare well, a minority present with extreme symptoms of depression and psychosomatic distress; female sex, low socio-economic status and treatment with intensive chemotherapy are important risk factors for a poor psychosocial outcome.
  • A well functioning network of pediatric oncologists, GP's, adult oncologists and other specialists of adult medicine must be developed in order to prevent, early detect and treat expected long-term toxicities.
  • [MeSH-major] Lymphoma. Radiotherapy / adverse effects. Survivors

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Dec;9(12):1990-6 [8609707.001]
  • [Cites] Cancer. 1976 Dec;38(6):2263-8 [826312.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] N Engl J Med. 1981 Jun 4;304(23):1377-82 [7231460.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 [9789061.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):977-89 [7074658.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):28-36 [15654275.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):74-8 [8649323.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4091-5 [11051261.001]
  • [Cites] Ann Neurol. 1999 Dec;46(6):834-41 [10589535.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Blood. 1996 Apr 1;87(7):3045-52 [8639928.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5735-41 [17179107.001]
  • [Cites] N Engl J Med. 1988 Jan 14;318(2):76-81 [3336397.001]
  • [Cites] Cancer. 1981 May 15;47(10):2368-74 [6791800.001]
  • [Cites] J Clin Oncol. 1984 Jun;2(6):571-7 [6547167.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):788-93 [1550144.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):569-77 [10080601.001]
  • [Cites] Swiss Med Wkly. 2001 Apr 7;131(13-14):180-7 [11345808.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2435-43 [10856104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):873-80 [2211255.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):345-59 [12877662.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):546-52 [8410505.001]
  • [Cites] JAMA. 1979 Oct 26;242(17):1877-81 [480620.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • (PMID = 18196290.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


10. Houchaymi Z, Helou S, Ballout J: [Pericardial tamponade and third-degree atrioventricular block revealing a primary cardiac lymphoma]. Rev Med Interne; 2010 Nov;31(11):e4-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pericardial tamponade and third-degree atrioventricular block revealing a primary cardiac lymphoma].
  • Secondary and primary cardiac tumors are rare, and primary cardiac lymphoma are exceptional.
  • Analysis of the pericardial fluid and tissue was not contributive.
  • À transvenous biopsy of the cardiac tumour revealed non-Hodgkin large B-cell lymphoma (CD45+ CD20+ CD3-BCl2+).
  • Therapy is based on chemotherapy.
  • However, prognosis remains poor for this type of tumor commonly revealed by a pericardial effusion.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20605278.001).
  • [ISSN] 1768-3122
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


11. Johri A, Baetz T, Isotalo PA, Nolan RL, Sanfilippo AJ, Ropchan G: Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome. Can J Cardiol; 2009 Jun;25(6):e210-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome.
  • Primary cardiac lymphomas are rare extranodal lymphomas that should be distinguished from secondary cardiac involvement by disseminated non-Hodgkin's lymphoma.
  • Cardiac lymphomas often mimic other cardiac neoplasms, including myxomas and angiosarcomas, and often require multimodality cardiac imaging, in combination with endomyocardial biopsy, excisional biopsy or pericardial fluid cytology, to establish a definitive diagnosis.
  • A 60-year-old immunocompetent man who presented with superior vena cava syndrome secondary to a right atrial, primary cardiac diffuse large B cell lymphoma (non-Hodgkin's lymphoma) is described in the present article.
  • The patient had no clinical evidence of disseminated lymphoma and was successfully treated with prompt surgical excision of his atrial mass, followed by anthracycline-based chemotherapy.
  • The patient required multi-modality cardiac imaging to accurately identify and plan surgical excision of his cardiac lymphoma.
  • The therapeutic management and clinical and radio-logical features of primary cardiac lymphoma are reviewed.
  • [MeSH-major] Heart Neoplasms / complications. Lymphoma, Large B-Cell, Diffuse / complications. Superior Vena Cava Syndrome / etiology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Superior vena cava syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Oct 15;80(8):1497-506 [9338475.001]
  • [Cites] Cardiovasc Pathol. 2009 Mar-Apr;18(2):92-9 [18402841.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1344-50 [17721189.001]
  • (PMID = 19536397.001).
  • [ISSN] 1916-7075
  • [Journal-full-title] The Canadian journal of cardiology
  • [ISO-abbreviation] Can J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2722499
  •  go-up   go-down


12. Avilés A, Neri N, Castañeda C, Talavera A, Huerta-Guzmán J, González M: Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Med Oncol; 2002;19(1):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma.
  • Anthracyclines remain as the best drugs in the treatment of patients with aggressive malignant lymphoma in combination with other cytotoxic drugs.
  • However, dose escalation is poorly tolerated and acute and late cardiac toxicity has limited the use of these compounds.
  • Pegylated liposomal doxorubicin has been proven to be useful in some malignancies, without the presence of acute cardiac toxicity and with a good response rate in patients with relapsed/refractory lymphomas.
  • We report the first study of this drug in combination chemotherapy in patients with previously untreated aggressive malignant lymphoma.
  • Twenty consecutive patients with diagnosis of diffuse large-B-cell lymphoma, age < 18 yr to < 70 yr, without previous treatment, HIV-negative high and high-intermediate clinical risks were treated with the CHOP-Bleo regimen at standard doses, using pegylated-liposomal doxorubicin instead of doxorubicin, at 25 mg/m2 (3 patients), 30 mg/m2 (3 patients), and 35 mg/m2 (14 patients).
  • Two patients died secondary to tumor progression.
  • Cardiac function was normal before and 12 mo after chemotherapy.
  • Pegylated liposomal doxorubicin appear as an promising drug in the treatment of patients with aggressive malignant lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Clin Lab Haematol. 2000 Apr;22(2):61-72 [10792394.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3185-91 [9336354.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):499-505 [9516942.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):987-93 [9060537.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1037-47 [10964334.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2981-95 [9256143.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Feb;127(2):128-34 [11216914.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):653-9 [9053490.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):711-6 [9739435.001]
  • [Cites] Leuk Lymphoma. 1997 Apr;25(3-4):319-25 [9168442.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):799-803 [7525515.001]
  • (PMID = 12025891.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 11056-06-7 / Bleomycin; 30IQX730WE / Polyethylene Glycols; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP-B protocol
  •  go-up   go-down


13. Jeddi R, Ben Abdennebi Y, Allani B, Belakhal R, Aissaoui L, Ben Abid H, Ali ZB, Meddeb B: [Tumor lysis syndrome]. Tunis Med; 2007 Feb;85(2):174-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The syndrome results from the destruction (or lysis) of a large number of rapidly dividing malignant cells spontaneously or during chemotherapy.
  • The resulting metabolic abnormalities include hyperkaliemia, hyperuricemia, and hyperphosphatemia with secondary hypocalcemia, all of which put patients at risk for renal failure and alteration in cardiac function.
  • The tumor lysis syndrome occurs most often in patients with large tumor burdens that are very sensitive to chemotherapy and radiotherapy, such as acute or chronic leukaemias with high leukocyte counts and high-grade lymphoma.
  • [MeSH-major] Tumor Lysis Syndrome / etiology. Tumor Lysis Syndrome / therapy
  • [MeSH-minor] Acute Kidney Injury / etiology. Acute Kidney Injury / therapy. Allopurinol / therapeutic use. Antimetabolites / therapeutic use. Fluid Therapy. Humans. Water-Electrolyte Imbalance / etiology. Water-Electrolyte Imbalance / therapy

  • Hazardous Substances Data Bank. Allopurinol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17665670.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Antimetabolites; 63CZ7GJN5I / Allopurinol
  • [Number-of-references] 26
  •  go-up   go-down


14. Erikci AA, Ozturk A, Tekgunduz E, Sayan O: Acute myeloid leukemia complicating multiple myeloma: a case successfully treated with etoposide, thioguanine, and cytarabine. Clin Lymphoma Myeloma; 2009 Aug;9(4):E14-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The association of acute leukemia and multiple myeloma (MM) has been usually described not only as a complication of chemotherapy but also in the absence of chemotherapy or together at the time of diagnosis.
  • CASE REPORT: We report a case of a 68-year-old female who developed AML 2 years after the diagnosis of light chain (kappa) myeloma.
  • The patient was treated with an anthracycline-lacking therapy consisting of etoposide 120 mg/m2, thioguanine 100 mg/m2 orally twice daily on 1-5 days, and cytarabine 40 mg/m2 subcutaneously on day 1 (ETC) because of poor cardiac performance.
  • CONCLUSION: Following ETC therapy our particular patient has been in complete hematologic remission for 29 months.
  • This therapy might be a safe alternative in secondary leukemia especially for elderly patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / therapeutic use. Etoposide / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Multiple Myeloma / drug therapy. Thioguanine / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged. Drug Administration Schedule. Female. Humans. Injections, Subcutaneous. Remission Induction


15. Canellos GP, Abramson JS, Fisher DC, LaCasce AS: Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol; 2010 Mar 20;28(9):1611-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy.
  • PURPOSE: Limited-stage Hodgkin's lymphoma (HL) has been treated with radiation alone or radiation combined with chemotherapy.
  • Although results in progression-free survival and overall survival have been excellent, the long-term, radiation-induced, toxic cardiac and secondary oncologic complications occurring in succeeding decades have compromised survival of young patients.
  • This study examines the impact of chemotherapy alone in treatment of limited-stage, nonbulky HL, radiation therapy eliminated from primary treatment.
  • The ABVD regimen was known to be curative in more advanced disease without radiation therapy.
  • Salvage therapy was successful with second-line chemotherapy/radiation and autologous stem-cell transplantation.
  • CONCLUSION: Six cycles of ABVD is an effective and safe treatment for limited-stage, nonbulky HL and would spare young patients radiation toxicity.
  • Interim positron emission tomography/computed tomography scans in current and future trials may identify those patients who require less than six cycles of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Retrospective Studies. Salvage Therapy. Treatment Outcome. Vinblastine / administration & dosage. Young Adult


16. Trifunovic D, Vujisic-Tesic B, Vuckovic M, Ostojic M, Ristic A, Bogdanovic A, Mihaljevic B, Andjelic B, Perunicic-Jovanovic M, Antonic Z: Multimodality imaging in the assessment of cardiac lymphoma presented as new-onset atrial fibrillation. Echocardiography; 2010 Mar;27(3):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality imaging in the assessment of cardiac lymphoma presented as new-onset atrial fibrillation.
  • Cardiac involvement by non-Hodgkin's lymphoma is not uncommon, however rarely diagnosed during life due to nonspecific clinical presentation.
  • We report a case of secondary cardiac lymphoma in patient who presented with new-onset atrial fibrillation.
  • Cardiac lymphoma was in a form of bulky right atrial mass, infiltrating the atrial septum and cavo-atrial junction with concomitant mild pericardial effusion.
  • In the present case, we illustrate complementary role of transthoracic, transesophageal echocardiography and multislice CT scan with three-dimensional reconstruction, in detection and evaluation of secondary cardiac tumor.
  • Usefulness of echocardiography to follow up the effects of chemotherapy is also shown.
  • [MeSH-major] Atrial Fibrillation / ultrasonography. Echocardiography. Heart Neoplasms / secondary. Heart Neoplasms / ultrasonography. Lymphoma, Non-Hodgkin

  • MedlinePlus Health Information. consumer health - Atrial Fibrillation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486963.001).
  • [ISSN] 1540-8175
  • [Journal-full-title] Echocardiography (Mount Kisco, N.Y.)
  • [ISO-abbreviation] Echocardiography
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lichtman SM, Petroni G, Schilsky RL, Johnson JL, Perri RT, Niedzwiecki D, Sklar J, Barcos M, Peterson BA: High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Leuk Lymphoma; 2001 Nov-Dec;42(6):1255-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
  • The main objectives of this study were to determine the feasibility of administering high doses of cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) every 14-21 days to patients with follicular small cleaved cell lymphoma.
  • For each patient, the treatment was not considered feasible if fewer than four cycles of cyclophosphamide chemotherapy could be administered on schedule (i.e. at least every 29 days) or (1) hospitalization of the patient for longer than three days was necessary for neutropenic fever (38 degrees C) or bacteriologically documented infection in > 50% of the cycles, or (2) grade > or = 2 hemorrhage in association with thrombocytopenia of grade > or = 3 severity occurred in > 50% of the cycles or (3) non-hematologic toxicity (excluding nausea/vomiting and alopecia) of grade > or = 3 occurred in > 50% of cycles.
  • The goal was to have a treatment program feasible in 75% or more of the treated patients.
  • The secondary objectives were to determine the toxicities, the complete and partial response rates, and the time to treatment failure (TTF).
  • The trial also attempted to assess the effectiveness of this treatment program in eradicating Bcl-2 rearrangements by PCR, and to assess complete remission duration in relationship to PCR results in patients who respond to this chemotherapy program.
  • Patients were required to have histologically documented non-Hodgkin's lymphoma of the subtypes follicular, predominantly small cleaved cell (IWF-B) or follicular mixed, (IWF-C).
  • Patients had to be between 18 and physiologic age 55 years (carefully selected patients over age 55 years were also eligible), expected survival > 2 years, performance status 0-1, and have adequate renal, hepatic and bone marrow function, and a cardiac ejection fraction > or = 50%.
  • The median follow-up time is 5.0 years, with a range of 2.5-6.7 years.
  • The 1-year estimated probability of freedom from treatment failure was 50% and of survival at 1 year was 92%.
  • Post-treatment specimens were submitted for seven of the 13 patients.
  • Four of the seven converted to Bcl-2 negative following treatment.
  • Eight of 13 Bcl-2 positive patients (62%) had a clinical response to treatment.
  • This study demonstrates that repetitive doses of cyclophosphamide at 4.5 g/m2 every two weeks with rhG-CSF support can be administered to selected younger patients with advanced follicular lymphoma with morphologic involvement of the bone marrow with acceptable non-hematologic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy


18. Prunier F, Revel F, Hemery Y, Glaser E, Beaufils P: [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases]. Arch Mal Coeur Vaiss; 2000 Nov;93(11):1333-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases].
  • Primary cardiac lymphoma is very rare.
  • Secondary localisations are more common, observed in 15 to 30% of autopsy series.
  • Clinical symptoms of cardiac involvement are rare, explaining the usual post-mortem diagnosis.
  • The presentation of cardiac involvement by arrhythmias and conduction defects is very uncommon.
  • The authors report two cases, the first of a 35 year old man in whom primary cardiac lymphoma presented with ventricular tachycardia complicated secondarily by complete atrioventricular block (AVB) with pseudo-inferior wall infarction.
  • The second case was a 37 year old man with a cutaneous T cell lymphoma in whom complete AVB was the first sign of a secondary cardiac localisation of his disease.
  • The finding of cardiac lymphoma should lead to aggressive chemotherapy as soon as possible.
  • [MeSH-major] Heart Block / etiology. Heart Neoplasms / secondary. Lymphoma, Non-Hodgkin / complications. Tachycardia, Ventricular / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11190461.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Avilés A, Delgado S, Fernández R, Talavera A, Neri N, Huerta-Guzmán J: Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol; 2002 Mar;68(3):144-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial.
  • OBJECTIVES: We evaluate the long-term results of a randomized clinical trial in patients with advanced stages (III and IV) of follicular lymphoma using chemotherapy or combined therapy (chemotherapy following by adjuvant radiotherapy in patients with nodal bulky disease).
  • MATERIAL AND METHODS: Between 1981 and 1995, patients with follicular lymphoma were treated with combined chemotherapy, mostly anthracycline-based regimens; patients who achieved complete response were randomly assigned either to receive adjuvant radiotherapy to sites or to nodal bulky disease or not (control group).
  • Acute and late toxicity were minimal; only four patients (<1%) developed myelodysplastic syndrome/acute leukemia.
  • Cardiac toxicity was 2%, but one case was lethal.
  • Thirty-six patients (8%) died secondary to unrelated causes, in complete remission.
  • CONCLUSIONS: The use of adjuvant radiotherapy in patients with poor-prognosis follicular lymphoma increases EFS and OS with minimal toxicity.
  • We feel that follicular lymphoma should be treated curatively because <80% of patients will be in first complete response at <20yr.
  • The use of adjuvant radiotherapy will be considered in the first line of treatment in this set of patients.
  • [MeSH-major] Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cause of Death. Combined Modality Therapy. Disease-Free Survival. Female. Heart Diseases / chemically induced. Humans. Male. Middle Aged. Myocardial Infarction / chemically induced. Neoplasm Staging. Prognosis. Recurrence. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12068794.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Denmark
  •  go-up   go-down


20. Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, Casagrande W, Pascutto C, Franchini P, Lazzarino M: Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res; 2006 Nov 1;12(21):6487-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
  • PURPOSE: To report on long-term events after short doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy and adjuvant radiotherapy in favorable early-stage Hodgkin's lymphoma.
  • EXPERIMENTAL DESIGN: We monitored late events and causes of death over 15 years (median follow-up, 120 months) in 120 patients with nonbulky stage IA-IIA Hodgkin's lymphoma, treated with four cycles of ABVD and limited radiotherapy.
  • Pulmonary and cardiac function tests were done throughout the follow-up.
  • Outcome measures included cause-specific mortality, standardized mortality ratio, and standardized incidence ratio for secondary neoplasia.
  • The risk of cardiovascular events at 5 and 12 years was 5.5% and 14%, with a median latent time of 67 months (range: 23-179 months) from the end of radiotherapy.
  • Pulmonary toxicity developed in 8% of patients; all had received mediastinal irradiation and the median time from radiotherapy to pulmonary sequelae was 76 weeks (range: 50-123 weeks).
  • The risk of secondary neoplasia at 5 and 12 years was 4% and 8%, respectively, with no cases of leukemia.
  • CONCLUSIONS: Long-term events were mostly related to radiotherapy; the role of short ABVD chemotherapy was very limited, as documented by fertility preservation and lack of secondary myelodysplasia/leukemia.
  • A proportion of patients died from causes unrelated to disease progression and the excess mortality risk was mostly due to the occurrence of secondary neoplasms and cardiovascular diseases.
  • A moderate dose reduction of radiotherapy from 40-44 Gy to 30-36 Gy did not decrease the risk of late complications; abolishing radiotherapy in nonbulky early-stage Hodgkin's lymphoma is being evaluated.
  • [MeSH-major] Cardiovascular Diseases / etiology. Hodgkin Disease / therapy. Lung Diseases / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / adverse effects. Bleomycin / therapeutic use. Dacarbazine / adverse effects. Dacarbazine / therapeutic use. Disease-Free Survival. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Fertility / drug effects. Fertility / radiation effects. Follow-Up Studies. Humans. Male. Middle Aged. Pregnancy. Radiotherapy, Adjuvant. Survival Analysis. Vinblastine / adverse effects. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085663.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


21. Herbertson R, Hancock BW: Hodgkin Lymphoma in adolescents. Cancer Treat Rev; 2005 Aug;31(5):339-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin Lymphoma in adolescents.
  • With the development of an integrated treatment approach, the cure rate and survival of patients with Hodgkin Lymphoma (HL) is now high.
  • Treatment tailored to stage, using chemotherapy, with or without involved field radiotherapy is the standard of care.
  • Paediatric oncologists have been developing treatment regimens to maximise cure rate whilst trying to minimise the associated late side-effects, and cure rates in children are now often greater than 90%.
  • Future treatment strategies may direct the treatment of adolescents with HL away from the current "adult" regimens, and closer to that currently received by children, but prospective randomised trials are required.
  • Rationalisation of both chemotherapy and radiotherapy administered to children and adolescents aims to minimise the risk of significant long-term side effects without sacrificing high cure rates.
  • Infertility, secondary malignancies, cardiac and respiratory morbidity are all significant risks of current combined modality treatment that need to be discussed when obtaining informed consent and may influence the choice of treatment offered or accepted.
  • Monitoring late effects of treatment (both physical and psychological) is especially important in this group of young patients.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951118.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 131
  •  go-up   go-down


22. Gaspar A, Salomé N, Nabais S, Brandão A, Simões A, Portela C, Salgado A, Pereira A, Correia A: Echocardiographic assessment of a cardiac lymphoma: beyond two-dimensional imaging. Eur J Echocardiogr; 2009 Dec;10(8):975-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Echocardiographic assessment of a cardiac lymphoma: beyond two-dimensional imaging.
  • Lymphoma is usually recognized as the third most frequent metastatic malignancy involving the heart.
  • In recent years, the incidence of cardiac lymphoma has increased, mainly because of HIV-infected patients.
  • We present a case of secondary cardiac lymphoma in an HIV patient presenting with heart failure.
  • Doppler tissue imaging (DTI) showed reduced systolic and diastolic velocities at mitral and tricuspid annulus, compatible with systolic and diastolic myocardial dysfunction, likely owing to infiltration.
  • After 2 weeks of chemotherapy, repeated exam showed significant reduction of the tumour mass and of the LV wall thickness, as well as normalized systolic and diastolic velocities at mitral and tricuspid annulus, as assessed by DTI.
  • Use of transthoracic echocardiography, mostly two-dimensional imaging, has been described for several years for the diagnosis of cardiac involvement as well as for the assessment of tumour regression in response to chemotherapy.
  • The present case report highlights the potential utility of other echocardiographic modalities, particularly DTI, for the assessment of cardiac lymphoma but also for monitoring the tumour response to adequate therapy.
  • [MeSH-major] Echocardiography / methods. Heart Neoplasms / ultrasonography. Lymphoma / ultrasonography
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. HIV Infections / complications. Humans. Male

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570800.001).
  • [ISSN] 1532-2114
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Matkowskyj KA, Wiseman WR, Robin JC, Norvell JP, Puthumana J, Nelson B, Peterson L, McGarry TJ, Tourtellotte WG: Therapy-related myelodysplastic syndrome presenting as fulminant heart failure secondary to myeloid sarcoma. J Hematop; 2010;3(1):41-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplastic syndrome presenting as fulminant heart failure secondary to myeloid sarcoma.
  • Rapidly progressive heart failure is commonly caused by an extensive myocardial infarction, a mechanical complication of infarction, myocarditis, or acute valvular insufficiency.
  • The patient presented with episodic shortness of breath, he was anemic and thrombocytopenic, and his bone marrow biopsy revealed myelodysplastic syndrome from treatment for oligodendroglioma.
  • His clinical course was characterized by a chronic leak of cardiac enzymes, a new right bundle branch block, and a large pericardial effusion causing tamponade and death from fulminant heart failure and ventricular arrhythmias within 2 weeks.
  • At autopsy, the heart was massively infiltrated with myeloblasts and other immature myeloid cells.
  • Cardiac infiltration in a patient with myelodysplastic syndrome is extremely rare, especially in the absence of bone marrow involvement by blasts.
  • The recognition of this entity is becoming increasingly important as the incidence of cardiac myeloid sarcoma may be on the rise as the number of patients receiving chemotherapy increases.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiol. 2001 Oct;38(4):219-24 [11688429.001]
  • [Cites] Acta Cardiol. 2003 Apr;58(2):155-8 [12715908.001]
  • [Cites] Echocardiography. 2003 Aug;20(6):539-44 [12859368.001]
  • [Cites] Cancer. 1965 Feb;18:253-8 [14254082.001]
  • [Cites] BMC Blood Disord. 2006;6:4 [16953890.001]
  • [Cites] Am J Hematol. 1987 Jul;25(3):325-32 [3300284.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):1011-9 [8372941.001]
  • [Cites] Med Clin (Barc). 1996 Apr 13;106(14):545-7 [8656744.001]
  • [Cites] J Am Soc Echocardiogr. 2004 Sep;17(9):1000-2 [15337968.001]
  • [Cites] Eur J Nucl Med. 1992;19(4):306-8 [1597247.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1081-4 [16019562.001]
  • [Cites] Acta Pathol Jpn. 1990 Dec;40(12):922-6 [2096594.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):983-5 [2390016.001]
  • [Cites] N Engl J Med. 1990 Feb 1;322(5):337-8 [2404207.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(3):237-45 [3152929.001]
  • [Cites] Am J Cardiol. 1968 Mar;21(3):388-412 [4295426.001]
  • [Cites] Cancer. 1973 Apr;31(4):948-55 [4513297.001]
  • [Cites] Am J Clin Pathol. 1995 Oct;104(4):431-43 [7572794.001]
  • (PMID = 21544187.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Grant] United States / NIH HHS / OD / K26 OD010945
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2883902
  • [Keywords] NOTNLM ; Leukemia cordis / Myeloid sarcoma / Rapidly progressive heart failure / Therapy-related myelodysplastic syndrome
  •  go-up   go-down


24. Barbaric D, Holley D, Lau KC, McCowage G: It is ALL in the heart: a patient with acute lymphoblastic leukemia and cardiac infiltration at time of diagnosis. Leuk Lymphoma; 2002 Dec;43(12):2417-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] It is ALL in the heart: a patient with acute lymphoblastic leukemia and cardiac infiltration at time of diagnosis.
  • We report an unusual case of acute lymphoblastic leukemia (ALL) in a 15-year-old boy where a mass lesion, presumed to be a cardiac metastasis, was noted in the right ventricular wall and cavity at the time of initial routine echocardiography.
  • The lesion resolved, without surgical intervention, following the institution of multi-agent chemotherapy.
  • [MeSH-major] Heart Neoplasms / secondary. Leukemic Infiltration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Brain Neoplasms / diagnosis. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Cerebrospinal Fluid / cytology. Combined Modality Therapy. Disease-Free Survival. Electrocardiography. Humans. Immunophenotyping. Male. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613535.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Cho JG, Ahn YK, Cho SH, Lee JJ, Chung IJ, Park MR, Kim HJ, Jeong MH, Park JC, Kang JC: A case of secondary myocardial lymphoma presenting with ventricular tachycardia. J Korean Med Sci; 2002 Aug;17(4):549-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of secondary myocardial lymphoma presenting with ventricular tachycardia.
  • Malignant lymphoma can involve the cardiac cavity or myocardium as a mass.
  • Clinical symptoms of its cardiac involvement are usually absent or nonspecific, making the diagnosis of the cardiac involvement very difficult before death.
  • We experienced a patient with secondary myocardial non-Hodgkin's lymphoma presenting with sustained ventricular tachycardia (VT) as a primary clinical problem.
  • Physical examination revealed rapid heart beat with variable intensity of the first heart sound and soft mass in the lower abdomen.
  • Cytological examination of aspirated pericardial fluid and percutaneous needle biopsy of the abdominal mass revealed a diffuse large cell type non-Hodgkin's lymphoma.
  • Myocardial masses and ventricular tachycardia resolved with chemotherapy using cyclophosphamide, adriamycin, vincristine and prednisone regimen.
  • [MeSH-major] Heart Neoplasms / pathology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / pathology. Myocardium / pathology. Tachycardia, Ventricular / etiology
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adult. Biopsy, Needle. Bundle-Branch Block. Echocardiography. Electrocardiography. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172054.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3054895
  •  go-up   go-down


26. Manojkumar R, Sharma A, Grover A: Secondary lymphoma of the heart presenting as recurrent syncope. Indian Heart J; 2001 Mar-Apr;53(2):221-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary lymphoma of the heart presenting as recurrent syncope.
  • Left cervical lymph node biopsy confirmed the diagnosis of non-Hodgkin's lymphoma.
  • The tumor resolved completely with chemotherapy without surgical intervention.
  • [MeSH-major] Heart Neoplasms / complications. Heart Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / diagnosis. Syncope / etiology
  • [MeSH-minor] Amiodarone / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Child. Cyclophosphamide. Doxorubicin. Echocardiography, Transesophageal. Electrocardiography. Follow-Up Studies. Humans. Male. Prednisolone. Recurrence. Tachycardia, Ventricular / etiology. Tomography, X-Ray Computed. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - Fainting.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11428484.001).
  • [ISSN] 0019-4832
  • [Journal-full-title] Indian heart journal
  • [ISO-abbreviation] Indian Heart J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; N3RQ532IUT / Amiodarone; VAP-cyclo protocol
  •  go-up   go-down


27. Podol'skiĭ PN, Datsenko PV, Pan'shin GA, Sotnikov VM, Mel'nik IuD, Ivashin AV, Bozhenko VK: [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma]. Vopr Onkol; 2009;55(4):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma].
  • A computer database was created to take care of a wide range of protocols for combined treatment of Hodgkin's disease stage I-IV (n=1,573).
  • Early-onset radiation-related injuries (pneumonitis) and exposure of lung tissues to radiation were identified as the main risk factors for cardiopathology development.
  • It is suggested that total focal dosage used after chemotherapy be reviewed since total dosage for the entire lymph collector in excess of 30 Gy might contribute to hazards of cardiopathology.
  • However, a locally administered TTD ranging 36-44 Gy to deal with residual tumor offers best advantage in preventing local relapse.
  • Our approach might promote individualization of prognosis as far as cardiac complications involved in Hodgkin's lymphoma are concerned.
  • [MeSH-major] Heart / radiation effects. Heart Diseases / etiology. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Heart Neoplasms / secondary. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pneumonia / etiology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Assessment. Risk Factors. Survival Analysis. Vincristine / administration & dosage


28. Pacifico N, Weishaar KM, Boozer LB, Nakamura RK: Full recovery after cardiac arrest secondary to accidental iatrogenic venous air embolism in a cat. J Vet Emerg Crit Care (San Antonio); 2010 Apr 1;20(2):264-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full recovery after cardiac arrest secondary to accidental iatrogenic venous air embolism in a cat.
  • OBJECTIVE: To describe the successful management of cardiac arrest following accidental venous air embolism (VAE) in a cat.
  • CASE SUMMARY: A 3-year-old spayed female domestic shorthair cat, weighing 4 kg, was presented for continuation of its chemotherapy protocol.
  • The cat was inadvertently administered approximately 5.5 mL of air IV during initiation of fluid therapy.
  • Immediate cardiac arrest resulted and CPR successfully achieved return of spontaneous circulation.
  • This is the first report of a cat surviving cardiac arrest secondary to VAE.
  • [MeSH-major] Cat Diseases / therapy. Embolism, Air / veterinary. Fluid Therapy / veterinary. Heart Arrest / veterinary. Iatrogenic Disease / veterinary
  • [MeSH-minor] Animals. Cardiopulmonary Resuscitation / veterinary. Cats. Female. Lymphoma, Non-Hodgkin / therapy. Lymphoma, Non-Hodgkin / veterinary. Oxygen Inhalation Therapy / methods. Oxygen Inhalation Therapy / veterinary. Treatment Outcome. Veins

  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20487256.001).
  • [ISSN] 1476-4431
  • [Journal-full-title] Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
  • [ISO-abbreviation] J Vet Emerg Crit Care (San Antonio)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Timperley J, Mitchell AR, Becher H: Primary cardiac lymphoma. Eur J Echocardiogr; 2003 Dec;4(4):327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac lymphoma.
  • We present a case of primary cardiac lymphoma, which is a rare condition compared with secondary metastatic involvement and is associated with poor prognosis.
  • This case demonstrates the use of transthoracic echocardiography for the assessment of tumour regression in response to chemotherapy.
  • [MeSH-major] Heart Neoplasms / ultrasonography. Lymphoma, B-Cell / ultrasonography
  • [MeSH-minor] Aged. Echocardiography. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14611830.001).
  • [ISSN] 1525-2167
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Khan NU, Ahmed S, Wagner P, Rumley RL, Movahed A: Cardiac involvement in non-Hodgkin's lymphoma: with and without HIV infection. Int J Cardiovasc Imaging; 2004 Dec;20(6):477-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac involvement in non-Hodgkin's lymphoma: with and without HIV infection.
  • AIDS has resulted in a significant increase in the incidence of both primary and secondary cardiac lymphomas.
  • Prognosis of HIV associate cardiac non-Hodgkin's lymphoma is poor with very limited survival.
  • Many cases of cardiac involvement in lymphoma remain undetected secondary to non-specific symptoms.
  • Chemotherapy may produce remission in some cases.
  • We report two cases of cardiac involvement with B-cell lymphoma.
  • [MeSH-major] HIV Infections / pathology. Heart Neoplasms / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Female. HIV Seronegativity. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Neoplasm Staging. Prognosis


31. Zhou SY, Shi YK, He XH, Han XH, Liu P, Yang JL, Zhou AP, Feng FY: [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases]. Ai Zheng; 2002 Apr;21(4):405-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
  • BACKGROUND & OBJECTIVES: High dose chemoradiotherapy (HDT) with autologous hemotopoietic stem cell transplantation (ASCT) has become one of the important salvaged treatments for the Hodgkin's Lymphoma(HL) patients with relapsed or resistant disease, but its role as the primary treatment remains indefinite.
  • This study was designed to further evaluate its status in the combined modality treatment, especially, to discuss its value in the primary treatment of the patients with advanced disease and poor prognosis.
  • Among them, 9 patients were primary treatment, and 2 patients were secondary treatment.
  • After induction treatment 4 cases achieved complete response (CR) and 7 cases achieved partial response (PR).
  • High dose chemotherapy combined with total body irradiation (TBI) or total lymph node irradiation(TLI)/subtotal lymph node irradiation(STLI) were applied in 7 cases and high dose chemotherapy alone was used in 4 cases as preparative treatment before transplantion.
  • RESULTS: These cases who had been CR before transplantation were consolidative therapy, and among the rest with PR, 2 cases achieved CR, 1 cases PR, and 4 cases stable disease(SD).
  • With a median follow-up of 13(1-84) months for all patients, all of them were alive at that time.
  • Three cases experienced relapse after transplant, one of them was EFS for 42 months again after a local relapsed site irradiation; the other two cases were being given further salvaged treatment now.
  • No obvious cardiac, hepatic, and nephritic toxicity was found, neither transplant relative mortality.
  • CONCLUSIONS: HDT combined with ASCT is a method that worth to be further study to treat the patients with advanced or relapsed Hodgkin's Lymphoma with poor prognosis.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Drug-Related Side Effects and Adverse Reactions. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Radiotherapy / adverse effects. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12452021.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Allegra A, Alonci A, Russo S, Cannavò A, Penna G, D'Angelo A, Bellomo G, Musolino C: Cardiac involvement in patients with hematologic malignancies. J Investig Med; 2010 Oct;58(7):859-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac involvement in patients with hematologic malignancies.
  • Authors have reviewed literature about the management of patients with cardiologic disease occurring secondary to hematologic pathology itself or its therapy, with a focus on infiltration of myocardium in acute and chronic leukemia, lymphoma, multiple myeloma, and hypereosinophilic syndrome.
  • Moreover, they evaluated chemotherapy-associated toxicity, particularly for new drugs such as monoclonal antibody therapy, tyrosine kinase inhibitors, arsenic trioxide, bortezomib, and epigenetic therapy.
  • In fact, cardiac toxicity may range from asymptomatic subclinical abnormalities, such as electrocardiographic changes and left ventricular ejection decline, to life-threatening events and lead to chemotherapy dose reduction and delay and, in some cases, for patients with severe side effects, discontinuation of treatment.
  • Finally, they discussed on the identification of early markers of cardiac injury and on cardiac stem cell therapy as a promising approach to facilitate myocardial regeneration.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Heart Diseases / chemically induced. Heart Diseases / complications. Hematologic Neoplasms / complications. Hematologic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683345.001).
  • [ISSN] 1708-8267
  • [Journal-full-title] Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • [ISO-abbreviation] J. Investig. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


33. Peretz NM, Goldberg H, Kuten A, Meller I, Krivoi E, Lorber A, Bentur L, Lightman A, Gorenberg V, Ben Arush-Weyl M: [Long-term sequelae of malignant tumors in childhood: consequences of late side-effects]. Harefuah; 2001 Feb;140(2):95-100, 192, 191
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 110 children with malignant diseases (leukemia excepted) who survived 5-20 years (median 9) post-therapy were followed (1996-1998).
  • The most common malignancies were brain tumors, lymphoma, retinoblastoma and Wilm's tumor.
  • There was no cardiac or renal damage and no second malignancy.
  • Treatment of brain tumor caused 98 late side-effects in 28 patients (sequelae-to-patient ratio [SPR] 3.3).
  • There were frequent late complications in those treated for retinoblastoma (SPR 1.8), and bone or soft tissue sarcomas (SPR 0.8).
  • It averaged only 0.5 in those treated with chemotherapy alone or in combination with surgery.
  • When considering secondary strategies, screening for early detection of late complications would enable immediate solutions, such as hormonal replacement or providing compensating skills for post-treatment disability.
  • [MeSH-major] Mental Disorders / epidemiology. Neoplasms / therapy. Nervous System Diseases / epidemiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / adverse effects. Brain Neoplasms / therapy. Child. Child, Preschool. Eye Neoplasms / therapy. Female. Follow-Up Studies. Humans. Infant. Kidney Neoplasms / therapy. Lymphoma / therapy. Male. Radiotherapy / adverse effects. Retinoblastoma / therapy. Survivors. Time Factors. Wilms Tumor / therapy






Advertisement